Oxtexs Limited Appoints Dr. Nicholas Edwards

Share Article

Newly-founded medical device company appoints doctor and former Accenture partner to be its first Chairman.

Dr Nicholas Edwards has been appointed Chairman of Oxtexs Limited. Dr Edwards qualified in medicine from Oxford University before joining Andersen Consulting (now Accenture) in 1986. He spent eighteen years there, including eight as a partner. During this time he was the global leader of its Pharmaceutical R&D business. Dr Edwards is also Chairman of MedInnovate, and Kinapse, and is an investor and supporter of several life science startups.

Oxtexs was established in 2011 to develop novel and intelligent hydrogel self-inflating tissue expanders. They will be used in scar reconstruction, and for the treatment of congenital craniofacial conditions and limb deformities. The devices will allow surgeons to accurately and predictably control the direction, the timing, and rate of in vivo expansion. This reduces the risk of soft tissue damage and associated complications, meaning that clinicians can treat more cases, at a lower cost, and with better results.

Nicholas Edwards said, “I am delighted to take on the role of Chairman of Oxtexs. This technology has great potential for widespread clinical use in some of the most complex and demanding surgical operations. We are very excited about this technology and are confident that it will lead to big improvements in outcomes for patients."

The appointment of Nicholas Edwards completes a busy few weeks for Oxtexs which started with CEO David Jackson securing £500,000 of seed funding.

David Jackson said, “It is a great endorsement of the potential of the company that Nicholas has agreed to join the Board of Oxtexs as its founding Chairman. He brings a wealth of experience in early stage medical device companies, and will make a massive contribution to the development and growth of our company.”

Oxtexs is currently establishing clean-room manufacturing facilities to scale-up production, and is in the process of setting-up clinical trials.

For further information, or to arrange interviews with Nicholas Edwards or David Jackson, please contact Robert Flavin – details at the top of first page. Further background information and a description of the science behind tissue expansion can be found at http://www.oxtexs.com

Notes to editors:
Image: Portrait of Dr Edwards available at http://www.oxtexs.com/news/images

Oxtexs Limited was incorporated in Spring 2011 as a spinout from the University of Oxford. In a short period it has attracted investors with strong track records of funding and supporting successful medical-based startups.

Dr Nicholas Edwards graduated in Physiological Sciences from The Queen’s College, Oxford in 1982 and then completed his training in Clinical Medicine (BM, BCh) at Oxford in 1985. After research into the use of Artificial Intelligence to perform medical diagnosis, he completed house jobs in Cardiology and General Surgery before joining Andersen Consulting in 1986. He spent 18 years with Andersen Consulting (now known as Accenture), including 8 years as a partner, and was the global leader of Accenture’s Pharmaceutical R&D business.

In 2005, he was one of the founders of Kinapse, and MedInnovate. He is an investor and supporter of several life science startups.

Nicholas is an Associate Fellow of Green Templeton College, Oxford and sits on their Development Committee. He is currently working on a Centre based within the University of Oxford developing better methods of translating medical innovations into useable treatments, with an initial focus on pharmaceutical R&D.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

robert Flavin
rob@cooperrepco.co.uk
0845 621 6222
Email >
Visit website